Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer
N. Lynn Henry(University of Michigan), Anna Maria Storniolo(Indiana University Health), Elizabeth Yakim(Indiana University Health), Suzanne Lemler, Anne Nguyen(Indiana University School of Medicine), Jill A. Hayden(Northwestern University), Vered Stearns(Johns Hopkins University), Daniel F. Hayes(University of Michigan–Ann Arbor), Lang Li(Nanjing Agricultural University), David A. Flockhart(Indiana University – Purdue University Indianapolis), Faouzi Azzouz(Indiana University Health), Zereunesay Desta(Indiana University Health), Karineh Tarpinian(Indiana University Health)
Cited by 391
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k